STIFEL 2026 HEALTHCARE CONFERENCE - PROTALIX BIOTHERAPEUTICS INC

Financial Performance:

• Q3 results contributed to cumulative revenue of $75.6 million, with full-year 2026 guidance of $78–$83 million expected to be met or exceeded.
• Cash and deposits stand at $48.5 million, providing sufficient liquidity to finance Phase 2 enrollment for the PRX115 (gout) program and operational costs.
• Revenue from Chiesi (Elfabri royalties/batches) is projected to range between $33–$35 million in 2026, representing a 50% year-over-year increase, though revenue recognition follows a batch delivery/inventory model rather than a strict one-to-one royalty correlation with partner sales.
• Brazil operations (Elelyz) generate steady revenue of $22–$25 million, with market share at approximately 25% versus competitors, and potential for future growth to reach $100M+ if regulatory trends continue.

Guidance and Future Outlook:

• Management anticipates strong 2026 financials driven by continued growth in Elfabri patient penetration and new market approvals for the four-week regimen.
• PRX115 Phase 2 enrollment is targeted for completion by Q1 2026, with top-line data readout expected approximately one year from today (Q1 2027).
• Long-term outlook includes a rare renal pipeline expected to mature into 4–6 programs between discovery and Phase 1 within two years.
• Future commercialization of PRX115 may involve a combination of self-commercialization and third-party partnerships by 2031 to maximize upside.

Business Segments and Product Lines:

• Elfabri (Fabry disease): Approved by Chiesi in the EU and US; recently received a 4-week dosing regimen approval in the EU (March 2024), with global expansion ongoing.
• Elelyz (Gaucher disease): Licensed to Pfizer globally (except Brazil); maintains a steady 25% market share in Brazil against Serozyme.
• PRX115 (Gout): Currently in Phase 2 for uncontrolled gout; utilizes a proprietary plant-based platform with optimized half-life allowing for once-every-4-to-8-week dosing compared to Amgen's daily bi-weekly Crisotexa.
• Rare Renal Program: Early-stage development focusing on unmet needs, with multiple assets in discovery or Phase 1 expected to emerge soon.
• Technology Platform: Utilizes a unique plant-based cell suspension system for expressing complex human proteins (EL-ELIZO, EL-FABRIO, GALT, PRX115).

Market and Competitive Landscape:

• Gout Market: Targets 150,000–200,000 uncontrolled gout patients in the US (subset of 11 million total); current market value for uncontrolled gout is estimated at $1.6B, projected to reach several billions by 2031.
• Competition: Primary competitor is Amgen's Crisotexa (approved once every two weeks); PRX115 aims to differentiate via reduced infusion frequency (4–8 weeks) and potential monotherapy (without methotrexate).
• Fabry Competition: Competes with Sanofi/Genzyme's Fabrazyme and BioMarin's GalaFold, but PRX115 offers a distinct delivery profile and improved quality of life.
• Partner Strength: Chiesi is a profitable, stable global health company with a top priority on the rare disease franchise, providing a strong commercial engine for Elfabri.

Risks and Challenges:

• Clinical Risk: Phase 2 study for PRX115 carries the risk of missing endpoints; success requires demonstrating robust immunogenicity, safety, and efficacy across multiple dosing arms.
• Revenue Volatility: Revenue from Chiesi fluctuates based on their inventory management and batch ordering schedules rather than direct patient sales volume, creating quarterly variance.
• Commercial Execution: Transitioning from partnership-dependent revenue to self-commercialization of PRX115 requires building internal infrastructure and market research validation.
• Regulatory Uncertainty: FDA approval for Phase 3 and eventual commercial launch depends on successful Phase 2 outcomes and specific discussions regarding pivotal study design.

Management Commentary and Tone:

• Tone is described as "professionally joyful" and highly confident, citing solid financial footing and successful drug launches.
• CEO emphasized the "huge upside" of the PRX115 program, describing a successful Phase 2 readout as a "home run" that could significantly enhance the company's business model.
• Management highlighted the "robust" statistical power of the Phase 2 gout study and the clear mechanism of action observed in Phase 1.
• CFO clarified the revenue model with Chiesi, urging investors to focus on annual trends rather than quarterly fluctuations to understand the true correlation.

Analyst Questions and Answers:

• Q: Trends on the 4-week Elfabri regimen? A: Approval in new markets (e.g., Brazil recently approved both 2-week and 4-week regimens) is driving penetration; the trend is positive and expected to continue.
• Q: How is PRX115 Phase 1 data supporting Phase 2 design? A: Phase 1 showed sustained enzyme activity (up to 40 days below 2 mg/dL at 36mg dose) and safety in hyperuricemic patients, validating the selection of the 36mg dose for Phase 2.
• Q: What defines success for Phase 2? A: Success involves hitting the primary efficacy endpoint (80% responder rate similar to Crisotexa) with favorable immunogenicity/safety, specifically if one arm allows for once-every-four-weeks dosing without methotrexate.
• Q: What is the strategy post-Phase 2? A: If endpoints are met, a single pivotal Phase 3 study will be initiated with the FDA; commercialization strategy (self vs. license) will be determined closer to the readout, with a strong preference for self-commercialization given increased company maturity.
• Q: Pipeline updates on rare renal diseases? A: Expecting 4–6 programs to reach Phase 1 within two years, though licensing ready-to-go Phase 2 assets is less likely due to current lack of commercial infrastructure.

Other Key Points:

• The company is well-positioned to finance its strategy without immediate need for external capital raises, thanks to strong cash reserves and royalty streams.
• PRX115 features a specific PEGylation (3.4 kilodalton bi-functional) and a C250 mutation designed to minimize immunogenicity while extending half-life.
• The company plans to initiate market research with three third-party potential partners (TPPs) for PRX115 well before the Phase 2 readout.
• The "once-in-four-weeks" approval for Elfabri in the EU is a major milestone, addressing the needs of the 70% of Fabry patients located outside the US.